Novozymes A/S (OTCMKTS:NVZMY) Shares Gap Down – What’s Next?

Posted by Brenda Bartman on Sep 4th, 2026

Novozymes A/S (OTCMKTS:NVZMY – Get Free Report)’s share price gapped down prior to trading on Friday . The stock had previously closed at $70.31, but opened at $66.58. Novozymes A/S shares last traded at $68.72, with a volume of 1,967 shares.

Analyst Ratings Changes

A number of brokerages recently weighed in on NVZMY. Zacks Research upgraded Novozymes A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, June 8th. Kepler Capital Markets raised Novozymes A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Two analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy”.

View Our Latest Stock Report on NVZMY

Novozymes A/S Stock Performance

The firm’s 50-day moving average price is $65.89 and its 200 day moving average price is $61.27. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.03 and a current ratio of 1.67. The company has a market cap of $28.27 billion, a price-to-earnings ratio of 43.16, a PEG ratio of 3.12 and a beta of 0.93.

Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) last issued its quarterly earnings results on Thursday, August 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.16). The company had revenue of $1.30 billion during the quarter, compared to the consensus estimate of $1.27 billion. Novozymes A/S had a net margin of 14.70% and a return on equity of 6.60%. On average, sell-side analysts anticipate that Novozymes A/S will post 2.47 EPS for the current year.

Institutional Trading of Novozymes A/S

A hedge fund recently raised its position in Novozymes A/S stock. Elefante Mark B boosted its stake in shares of Novozymes A/S (OTCMKTS:NVZMY – Free Report) by 73.5% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 5,900 shares of the biotechnology company’s stock after purchasing an additional 2,500 shares during the period. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 at the end of the most recent quarter. Institutional investors own 0.03% of the company’s stock.

About Novozymes A/S

(Get Free Report)

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).